Diagnosis and approach to posttransplant diabetes

Current Diabetes Reports

Volumn 9, Issue 4, 2009, Pages 317-323

  Bonato, Vittoria ^b   Cataldo, Dorica ^b   Dotta, Francesco ^a   Carmellini, Mario ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; CORTICOSTEROID; CYCLOPHILIN A; CYCLOSPORIN A; EXENDIN 4; FK 506 BINDING PROTEIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INTERLEUKIN 2; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; NATEGLINIDE; PHENYLETHANOLAMINE N METHYLTRANSFERASE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; UNINDEXED DRUG;

BINDING SITE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENZYME INHIBITION; ETHNICITY; FRACTURE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GRAFT REJECTION; HEART FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LYMPHOCYTE ACTIVATION; MACROPHAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; POSTTRANSPLANT DIABETES MELLITUS; PREVALENCE; RETINA MACULA EDEMA; REVIEW; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; SMOKING CESSATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT INDICATION; UPREGULATION; VOMITING; WEIGHT GAIN;

DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; HUMANS; RISK FACTORS; TRANSPLANTATION;

EID: 67849085241     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-009-0049-y     Document Type: Review

References (35)

1. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003, 3:178-185.
2. Joss N, Staatz CE, Thomson AH, Jardine AG: Predictors of new onset diabetes after renal transplantation. Clin Transplant 2007, 19:136-143.
3. Miles AM, Sumrani N, Horowitz R, et al.: Diabetes mellitus after renal transplantation: As deleterious as non-transplant-associated diabetes? Transplantation 1998, 65:380-384.
4. Hjelmesaeth J, Hartmann A, Leivestad T, et al.: The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006, 69: 588-595.
5. Pham PT, Pham PC, Lipshutz GS, Wilkinson AH: New onset diabetes mellitus after solid organ transplantation. Endocrinol Metab Clin North Am 2007, 36:873-890.
6. John PR, Thuluvath PJ: Outcome of patients with new onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 2002, 8:708-713.
7. Vincenti F, Friman S, Scheuermann E, et al., on behalf of the DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C2 Monitoring Versus Tacrolimus) Investigators: Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transpl 2007, 7:1506-1514.
8. Montori VM, Basu A, ErwiA PJ, et al.: Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002, 25:583-592.
9. Kamar N, Mariat C, Delahousse M, et al., on behalf of the Diapason Study Group: New onset diabetes mellitus incidence and risk factors in kidney transplantation: Results of the observational cross-sectional study diapason. Transpl Proc 2006, 38:2295-2297.
10. Ollech JE, Kramer MR, Peled N, et al.: Post-transplant diabetes mellitus in lung transplant recipients: Incidence and risk factors. Eur J Cardiothorac Surg 2008, 33:844-848.
11. Midtvedt K, Hjelmesaeth J, Hartmann A, et al.: Insulin resistance after renal transplantation: The effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004, 15:3233-3239.
12. Goldberg PA: Comprehensive management of post-transplant diabetes mellitus: From intensive care to home care. Endocrinol Metab Clin North Am 2007, 36:907-922.
13. Bayès B, Granada ML, Pastor MC, et al.: Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation. Am J Transpl 2007, 7:416-422.
14. Doyle ME, Egan MJ: Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev 2007, 55:105-131.
15. Arner P, Gunnarson R, Blomdahl S, Groth CG: Some characteristics of steroid diabetes: A study in renal-transplant recipients receiving high dose corticosteroid therapy. Diabetes Care 1983, 6:23-25.
16. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2007, 30(Suppl 1):S42-S47.
17. Andrews RC, Walker BR: Glucocorticoids and insulin resistance: Old hormones, new targets. Clin Sci 1999, 96:513-523.
18. Delaunay F, Khan A, Cintra A, et al.: Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest 1997, 100:2094-2098.
19. Crabtree GR: Calcium, calcineurin and the control of transcription. J Biol Chem 2001, 276:2313-2316.
20. Crabtree GR, Olson EN: NFAT signaling. Choreographing the social lives of cells. Cell 2002, 109:S67-S79.
21. Lawrence MC, Bhatt HS, Watterson JM, Easom RA: Regulation of insulin gene transcription by a Ca(2+)-responsive pathway involving calcineurin and nuclear factor of activated T cells. Mol Endocrinol 2001, 10:1758-1767.
22. Tamura K, Fujimura T, Tsutsumi T, et al.: Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation 1995, 59:1606-1613.
23. Valantine H, Rickenbaker P, Kemna M, et al.: Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease. Circulation 2001, 103:2144-2152.
24. Davidson J, Wilkinson A, Dantal J, et al.; International Expert Panel: New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an International Expert Panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003, 75(Suppl 10):S3-S24.
25. Luan FL, Steffick DE, Gadegbeku C, et al.: Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transplant 2009, 9:160-168.
26. Shah A, Kendall G, Demme RA, et al.: Home glucometer monitoring markedly improves diagnosis of post renal transplant diabetes mellitus in renal transplant recipients. Transplantation 2005, 80:775-781.
27. Ghisdal L, Bouchta NB, Broeders N, et al.: Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: A single-centre experience in renal transplanted patients and review of the literature. Transpl Int 2008, 21:146-151.
28. Sharif A, Moore R, Baboolal K: Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 2008, 85:353-358.
29. Kurian B, Joshi R, Helmuth A: Effectiveness and longterm safety of thiazolidinediones and metformin in renal transplant recipients. Endocrinol Pract 2008, 14:979-984.
30. Pietruck F, Kribben A, Van TN, et al.: Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. Transpl Int 2005, 18: 483-486.
31. Baldwin D Jr, Duffin KE: Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation 2004, 77:1009-1014.
32. Villaneuva G, Baldwin D: Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation 2005, 80:1402-1405.
33. Voytovich MH, Simonsen C, Jenssen T, et al.: Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrol Dial Transplant 2005, 20:413-418.
34. Türk T, Pietruck F, Dolff S, et al.: Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 2006, 6:842-846.
35. Nathan DM, Buse JB, Davidson MB, et al.: Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006, 29:1963-1972.